Skip to main content
Equibles

CRDL · Cardiol Therapeutics Inc.

Use CRDL with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CRDL.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
1.4100 CAD +0.0800 (+6.02%) At close · Nov 6 Intraday price with Plus
Rebalance outlook locked

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Investor day
Close1.4100 CAD Open1.3800 CAD Day1.3350–1.4100 CAD 52W close1.2800–3.1600 CAD Avg vol 30d174K DataJan 2020–Nov 2026

Latest documents

2026
Nov 3
Current report 6-K
US$75,000,000 common share sale agreement

Cardiol Therapeutics Inc. agreed with Jefferies LLC to issue and sell common shares with an aggregate offering price of up to US$75,000,000.

Read from the first part of this long document
Source passage
Cardiol Therapeutics Inc., a corporation organized under the laws of the Province of Ontario, Canada (the “Company”), confirms its agreement (this “Agreement”) with Jefferies LLC (the “Agent”) to issue and sell common shares of the Company (the “Common Shares”) having an aggregate offering price of up to US$75,000,000 (the “Shares”) upon and subject to the terms and conditions contained herein. Open the document at this passage
Nov 3
Current report 6-K
US$75 million ATM equity program launched

Cardiol Therapeutics Inc. entered an agreement with Jefferies LLC to offer and sell up to US$75 million under an at-the-market program. The company has no obligation to sell any shares, and proceeds would support CardiolRx and CRD-38 development.

4 source passages
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it has entered into a sales agreement (the "ATM Agreement") with Jefferies LLC (the "Sales Agent") for an at-the-market offering program (the "ATM Program"). The ATM Agreement will allow the Company to offer and sell up to US$75 million of common shares of the Company (the "Offered Shares") under the ATM Program. The timing and extent of the use of the ATM Program will be at the discretion of the Company, and the Company has no obligation to sell any shares pursuant to the ATM Program. As outlined in the Supplement, the Company intends to use the net proceeds of any such sales under the ATM Program to support the development of CardiolRx™ for the treatment of recurrent pericarditis including, subject to the Phase III MAVERIC trial outcomes, supporting a New Drug Application, to support the clinical development of CRD-38 and for general and administrative expenses, working capital and other expenses. Open the document at this passage
Nov 3
Offering documents SEDAR+
4 offering documents
  • Auditors' consent letter 1
  • Other material contract(s) 1
  • Shelf prospectus (NI 44-102) 1
  • Consent letter of issuer's legal counsel 1
Sep 23
Current report 6-K
Current report

Cardiol Therapeutics Inc. reached 110-patient MAVERIC enrollment target ahead of schedule and plans expansion to up to 150 patients after fewer-than-expected recurrences. Topline results are anticipated in mid-2027, versus previous Q1 2027 guidance; cash runway extends into Q1 2028.

All documents

Technicals

trend & momentum for long-term holders illustrative — not investment advice
Price context
position in its 52-week range
Range low 1.2800 CAD Now 1.4100 CAD · 7% Range high 3.1600 CAD
vs 200-day avg -22% vs 50-day avg -35%

Illustrative technical + ownership context — a signal mix, not investment advice.

Performance

5D 20D 120D MTD YTD
XTSE:CRDL -13.0% -23.8% -22.1% -13.0% +7.6%

Exchange listing

Market
XTSE
Ticker
CRDL
ISIN
—
Security
Ordinary share
Trading currency
CAD

Company with tickers: CRDL

Company

Website
https://www.cardiolrx.com/
Investor relations
https://www.cardiolrx.com/investor-relations/

Other listings of this company

Share classes and depositary receipts can have different prices and dividends.

Latest price

Plus & Pro

Follow CRDL during the session: the latest price, the day's change, range and volume. Closing prices stay free.

View plans Sign in

Recent dividends

No verified dividend payments are available for this listing yet.

Upcoming investor events

No upcoming investor events are listed for this company yet.

Earnings calls

  • Conference · September 2026 2026-09-14 Audio Transcript
    Cardiol Therapeutics Fireside Chat at H.C. Wainwright's 28th Annual Global Investment Conference
  • Conference · August 2026 2026-08-11 Audio Transcript
    Cardiol Therapeutics Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference
  • Conference · May 2026 2026-05-19 Audio Transcript
    Cardiol Therapeutics (CRDL) Fireside Chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ